These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 9473178)

  • 1. Rails, ReoPro, and the real world.
    O'Neill WW
    Cathet Cardiovasc Diagn; 1998 Jan; 43(1):7-8. PubMed ID: 9473178
    [No Abstract]   [Full Text] [Related]  

  • 2. Potent complementary clinical benefit of abciximab and stenting during percutaneous coronary revascularization in patients with diabetes mellitus: results of the EPISTENT trial.
    Lincoff AM
    Am Heart J; 2000 Feb; 139(2 Pt 2):S46-52. PubMed ID: 10650316
    [No Abstract]   [Full Text] [Related]  

  • 3. Stents are the CADILLAC of care. Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications.
    SoRelle R
    Circulation; 2002 Apr; 105(14):e9094-5. PubMed ID: 11942340
    [No Abstract]   [Full Text] [Related]  

  • 4. Routine use of abciximab in coronary stenting?
    Stables RH
    Lancet; 1998 Jul; 352(9122):81-2. PubMed ID: 9672267
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term clinical benefits of a platelet glycoprotein IIb/IIIa receptor blocker, abciximab (ReoPro), in high-risk diabetic patients undergoing percutaneous coronary intervention.
    Sim DS; Jeong MH; Kim W; Rhew JY; Yum JH; Kim JH; Cho JG; Ahn YK; Park JC; Ahn BH; Kim SH; Kang JC
    Korean J Intern Med; 2003 Sep; 18(3):129-37. PubMed ID: 14619381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Readministration of abciximab in percutaneous coronary intervention.
    Fry ET
    J Invasive Cardiol; 1999 Apr; 11(4):251-8. PubMed ID: 10745525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of clopidogrel pretreatment before percutaneous coronary intervention in patients treated with glycoprotein IIb/IIIa inhibitors (abciximab or tirofiban).
    Assali AR; Salloum J; Sdringola S; Moustapha A; Ghani M; Hale S; Schroth G; Fujise K; Anderson HV; Smalling RW; Rosales OR
    Am J Cardiol; 2001 Oct; 88(8):884-6, A6. PubMed ID: 11676953
    [No Abstract]   [Full Text] [Related]  

  • 8. [Gastrointestinal bleeding in a patient with acute myocardial infarction treated with primary coronary angioplasty and abciximab (ReoPro) administration].
    Gziut AI; Pastwa Ł; Słysz A
    Kardiol Pol; 2006 Mar; 64(3):334-6; discussion 337-8. PubMed ID: 16583343
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of abciximab on myocardial salvage in patients with acute myocardial infarction undergoing primary angioplasty.
    Lee CW; Moon DH; Hong MK; Lee JH; Choi Si; Yang HS; Kim JJ; Park SW; Park SJ
    Am J Cardiol; 2002 Dec; 90(11):1243-6. PubMed ID: 12450607
    [No Abstract]   [Full Text] [Related]  

  • 10. Will blocking the platelet save the diabetic?
    King SB; Mahmud E
    Circulation; 1999 Dec 21-28; 100(25):2466-8. PubMed ID: 10604881
    [No Abstract]   [Full Text] [Related]  

  • 11. Abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profile.
    Kereiakes DJ; Lincoff AM; Anderson KM; Achenbach R; Patel K; Barnathan E; Califf RM; Topol EJ; ; ;
    Am J Cardiol; 2002 Sep; 90(6):628-30. PubMed ID: 12231090
    [No Abstract]   [Full Text] [Related]  

  • 12. Angiographic predictors of adverse outcomes in the modern interventional era.
    White CJ
    J Am Coll Cardiol; 2003 Sep; 42(6):989-90. PubMed ID: 13678917
    [No Abstract]   [Full Text] [Related]  

  • 13. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy.
    Marso SP; Lincoff AM; Ellis SG; Bhatt DL; Tanguay JF; Kleiman NS; Hammoud T; Booth JE; Sapp SK; Topol EJ
    Circulation; 1999 Dec 21-28; 100(25):2477-84. PubMed ID: 10604884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness of abciximab for treatment of early coronary artery stent thrombosis.
    Casserly IP; Hasdai D; Berger PB; Holmes DR; Schwartz RS; Bell MR
    Am J Cardiol; 1998 Oct; 82(8):981-5. PubMed ID: 9794358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double vessel occlusions after balloon angioplasty treated by stenting and subsequently by abciximab infusion.
    Bertrand OF; Meerkin D; de Guise P; Crépeau J; Bourassa MG
    Can J Cardiol; 2000 Jan; 16(1):83-5. PubMed ID: 10653937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of restenosis after angioplasty.
    Cahill MR; Macey MG; Dawson JR; Newland AC
    Lancet; 1994 May; 343(8909):1361. PubMed ID: 7910347
    [No Abstract]   [Full Text] [Related]  

  • 17. Attainment and maintenance of platelet inhibition through standard dosing of abciximab in patients undergoing percutaneous coronary intervention.
    Kereiakes DJ
    Circulation; 2000 Dec; 102(25):E186. PubMed ID: 11120710
    [No Abstract]   [Full Text] [Related]  

  • 18. On the use of abciximab in percutaneous coronary intervention.
    Iversen AZ
    Dan Med Bull; 2011 Aug; 58(8):B4312. PubMed ID: 21827726
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of abciximab pretreatment in patients with acute myocardial infarction undergoing primary angioplasty.
    Zorman S; Zorman D; Noc M
    Am J Cardiol; 2002 Sep; 90(5):533-6. PubMed ID: 12208418
    [No Abstract]   [Full Text] [Related]  

  • 20. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
    Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
    N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.